hydroxocobalamin
Trade name: cyanokit
Approved
Apr 18, 1975
Hydroxocobalamin (also hydroxycobalamin, OHCbl) is a natural form, or vitamer, of vitamin B12. It is a member of the cobalamin family of compounds. Hydroxocobalamin, the active ingredient in Cyanokit, is cobinamide dihydroxide dihydrogen phosphate (ester), mono (inner salt), 3’-ester with 5,6-dimethyl-1-α-D-ribofuranosyl-1H-benzimidazole. The drug substance is the hydroxylated active form of vitamin B12 and is a large molecule in which a trivalent cobalt ion is coordinated in four positions by a tetrapyrol (or corrin) ring. It is a hygroscopic, odorless, dark red, crystalline powder that is freely soluble in water and ethanol, and practically insoluble in acetone and diethyl ether. Cyanokit contains hydroxocobalamin, an antidote indicated for the treatment of known or suspected cyanide poisoning. Cyanide is an extremely toxic poison. In the absence of rapid and adequate treatment, exposure to a high dose of cyanide can result in death within minutes due to the inhibition of cytochrome oxidase resulting in arrest of cellular respiration. Specifically, cyanide binds rapidly with cytochrome a3, a component of the cytochrome c oxidase complex in mitochondria. Inhibition of cytochrome a3 prevents the cell from using oxygen and forces anaerobic metabolism, resulting in lactate production, cellular hypoxia and metabolic acidosis. In massive acute cyanide poisoning, the mechanism of toxicity may involve other enzyme systems as well. Signs and symptoms of acute systemic cyanide poisoning may develop rapidly within minutes, depending on the route and extent of cyanide exposure. The action of Cyanokit is based on its ability to bind cyanide ions. Each hydroxocobalamin molecule can bind one cyanide ion by substituting it for the hydroxo ligand linked to the trivalent cobalt ion, to form cyanocobalamin, which is then excreted in the urine. — NCATS
Clinical trial activity
28 trials · 36 clinical orgs · 7 marketing orgs
Earliest trial started Nov 1, 1998 (NCT00097669)
Timeline
1970s
1980s
- May 1, 1981
Belmar Pharmacy — Marketing Organization
- Jun 15, 1982
Abraxis — Marketing Organization
Indications
Approved for
Studied for
- Anemia · Phase 4
- Anemia, Iron-Deficiency · Phase 4
- Anemia, Pernicious · Phase 4
- Avitaminosis · Phase 2/Phase 3
- Breast Neoplasms · Phase 2
- Cognitive Dysfunction · Phase 4
- Colitis, Ulcerative · Phase 2
- Coronary Artery Disease · Phase 2
- Dementia · Phase 4
- Growth and Development · Phase 2/Phase 3
- Heart Valve Diseases · Phase 2
- Hydroxocobalamin · Phase 4
- Hypotension · Phase 2
- Liver Transplantation · Phase 4
- Malnutrition · Phase 2/Phase 3
- Migraine Disorders · Phase 2
- Migraine with Aura · Phase 2
- Migraine without Aura · Phase 2
- Orthognathic Surgery · Phase 2/Phase 3
- Pain · Phase 2
- Pregnancy · Phase 3
- Prognathism · Phase 2/Phase 3
- Propionic Acidemia · Phase 3
- Retrognathia · Phase 2/Phase 3
- Shock, Septic · Phase 2
- Somatosensory Disorders · Phase 2/Phase 3
- Vasoplegia · Phase 4
- Vitamin B 12 Deficiency · Phase 4
Mechanism of action
- CyanideSEQUESTERING AGENT
Cyanide sequestering agent
Approval history
- approvedApr 18, 1975
Chemistry & pharmacology
SMILES
[OH-].[Co+3].C[C@H](CNC(=O)CC[C@]1(C)[C@@H](CC(N)=O)[C@H]2[N-]C1=C(C)C3=NC(=CC4=NC(=C(C)C5=N[C@]2(C)[C@@](C)(CC(N)=O)[C@@H]5CCC(N)=O)[C@@](C)(CC(N)=O)[C@@H]4CCC(N)=O)C(C)(C)[C@@H]3CCC(N)=O)OP([O-])(=O)O[C@@H]6[C@@H](CO)O[C@@H]([C@@H]6O)N7C=NC8=C7C=C(C)C(C)=C8- Mol. weight
- 1346.3551 g/mol
- Chirality
- Racemic Mixture
- Inorganic
- No
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaHydroxocobalamin ↗
- NCATSQ40X8H422O ↗
- ChEMBLCHEMBL2103737 ↗
Also known as
- acetatocobalamin
- alpharedisol
- alpharedisol
- berocca
- cobalin-h
- cobalin-h
- cyanokit
- cyanokit
- cyanokit
- cyanokit
- hepavit
- hydrocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin
- hydroxocobalamin acetate
- hydroxocobalamin acetate
- hydroxocobalamin acetate
- hydroxocobalamin acetate
- hydroxocobalamin acetate
- hydroxocobalamin anhydrous
- hydroxocobalamin anhydrous
- hydroxocobalamine
- hydroxocobalamine
- hydroxocobalamine
- hydroxocobalaminum anhydrous
- hydroxocobalaminum anhydrous
- hydroxocobemine
- hydroxocobemine
- hydroxocobemine
- hydroxomin
- hydroxomin
- hydroxycobalamin
- hydroxycobalamin
- hydroxycobalamin
- hydroxycobalamin
- hydroxycobalamine
- hydroxycobalamine acetate
- hydroxy vitamin b12
- megamilbedoce
- neo-cytamen
- neo-cytamen
- oh-cbl
- oh-cbl
- vitamin b12
- vitamin b12
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07163364 | Phase 3 | Aug 31, 2025 | Shijiazhuang Pharma Group (CSPC) |
| NCT05536596 | Phase 2/Phase 3 (Phase 3) | Sep 30, 2022 | Universidad de los Andes, Universitat Internacional de Catalunya |
| NCT04627181 | Phase 4 | Nov 30, 2020 | Christian Medical College, Vellore, India |
| NCT04259060 | Phase 2 | Jun 30, 2020 | Harvard University |
| NCT06160219 | Phase 2/Phase 3 (Phase 3) | Aug 28, 2019 | Ain Shams University |
| NCT04054999 | Phase 4 | Aug 12, 2019 | Mayo Clinic |
| NCT03783091 | Phase 2 | Jul 31, 2019 | Medical College of Wisconsin |
| NCT03735316 | Phase 2 | Apr 25, 2019 | Mayo Clinic |
| NCT03446599 | Phase 2 | Nov 30, 2018 | Dartmouth University |
| NCT03372447 | Phase 4 | Dec 27, 2017 | Universidad Autonoma de Nuevo Leon |
| NCT02795572 | Phase 2 | Jun 1, 2017 | University of Calgary |
| NCT03069313 | Phase 2 | Oct 19, 2015 | Texas Tech University |
| NCT02272842 | Phase 2/Phase 3 (Phase 3) | Apr 20, 2015 | Tribhuvan University, Uni Health, Uni Research, Norway, University of Bergen |
| NCT02270749 | Phase 4 | Oct 1, 2014 | Rijnstate Hospital |
| NCT02832726 | N/A | Jan 1, 2014 | Aarhus University |
| NCT01690962 | N/A | Nov 1, 2012 | Physicians Committee for Responsible Medicine |
| NCT02457507 | Phase 4 | Aug 1, 2011 | Chinese University of Hong Kong |
| NCT01795131 | Phase 2/Phase 3 (Phase 3) | Feb 1, 2010 | International Center for Diarrheal Disease Research |
| NCT01201005 | N/A | Jul 1, 2009 | University of Bergen |
| NCT00939718 | N/A | Apr 1, 2009 | Aga Khan University |
Organizations
Research & Development (36)
Marketing (10)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abraxis | For profit | MKTG | Jun 15, 1982 |
| Actavis | For profit | MKTG | Aug 16, 1978 |
| Actavis | For profit | SYN | Aug 16, 1978 |
| BTG | For profit | MKTG | Dec 15, 2006 |
| BTG | For profit | NDA2 | Dec 15, 2006 |
| Belmar Pharmacy | For profit | MKTG | May 1, 1981 |
| Merck | For profit | NDA | Apr 18, 1975 |
| Merck | For profit | MKTG | Apr 18, 1975 |
| Serb SA | For profit | NDA2 | Dec 15, 2006 |
| Watson Pharmaceuticals | For profit | MKTG | — |